Shanghai HeartCare Calls H Shareholders’ Meeting to Approve Domestic Share Issuance Plan

Shanghai Heartcare Medical Technology Corp. Ltd. Class H ( (HK:6609) ) has shared an announcement.

Shanghai HeartCare Medical Technology Corporation Limited has convened a 2026 first class meeting of its H shareholders to be held in Shanghai on 16 January 2026, immediately after an extraordinary general meeting, to vote on several key capital-related matters. H shareholders will consider a proposed issuance of domestic shares under a specific mandate, the ratification of a subscription agreement with investor Zhang Han, authorization for the board to handle all matters related to the issuance, and approval for the issuance to proceed on a non-pre-emptive basis, a move that could broaden the company’s funding channels but may dilute existing shareholdings; the notice also sets out procedural requirements for proxy appointments, share transfer cut-off dates and voting eligibility, underscoring the corporate governance steps around this potential capital-raising exercise.

The most recent analyst rating on (HK:6609) stock is a Hold with a HK$47.00 price target. To see the full list of analyst forecasts on Shanghai Heartcare Medical Technology Corp. Ltd. Class H stock, see the HK:6609 Stock Forecast page.

More about Shanghai Heartcare Medical Technology Corp. Ltd. Class H

Shanghai HeartCare Medical Technology Corporation Limited is a China-based medical technology company listed in Hong Kong, focused on developing and commercializing cardiovascular and related interventional medical devices and solutions for both domestic and international markets.

Average Trading Volume: 56,626

Technical Sentiment Signal: Buy

Current Market Cap: HK$2.09B

See more insights into 6609 stock on TipRanks’ Stock Analysis page.